A team of investigators conducted a double-blind, placebo-controlled, phase 3 trial to assess outcomes following olaparib treatment in patients with BRCA 1/2-mutated, relapsed ovarian cancer.
The number of genes tested for ovarian and breast cancer has grown, but most patients do not undergo testing, and variant-of-unknown-significance results are common, especially among minority populations.
Increased risk for breast cancer observed, which was seen for up to two years after discontinuation of oral contraceptives.
[Cancer Management and Research] Retrospective review sought to determine how residual tumor diameter and number of cycles of adjuvant chemotherapy after surgery influenced prognosis for patients with OCCC.
Access a detailed treatment regimen chart for ovarian cancer, with a focus on primary chemotherapy/primary adjuvant therapy with IV and IP options.
Use of neoadjuvant chemotherapy for patients with stage IIIC and IV epithelial ovarian cancer has increased from 2004 to 2016.
Hyperthermic intraperitoneal chemotherapy added to cytoreductive surgery improved outcomes compared with surgery alone in a cohort study.
In a review of data from the Nationwide Readmissions Database, researchers found that women with ovarian cancer classified as frail were at higher risk for need of intensive care, nonroutine discharge, and readmissions after surgery.
Broad use of PARP inhibitors to treat advanced-stage ovarian cancer would be associated with high costs compared with their biomarker-directed use.
Researchers identified factors for increased risk of clinically significant fatigue among women who underwent surgery for gynecologic cancers.
